Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Endonovo Therapeutics, Inc. (ENDV : OTC)

• Company Description    Endonovo Therapeutics, Inc. is a biotechnology company which is engaged in developing a bioelectronic approach to regenerative medicine. The company's Immunotronics(TM) platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo's Cytotronics(TM) platform provides method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies. Endonovo Therapeutics, Inc. is headquartered in Woodland Hills, California. Number of Employees: 1

• Price / Volume Information    Yesterday's Closing Price: $0.01 Daily Weekly Monthly 20 Day Moving Average: 184,368 shares Shares Outstanding: 139.58 (millions) Market Capitalization: $1.35 (millions) Beta: 2.04 52 Week High: $0.06 52 Week Low: $0.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -46.11% -39.30% 12 Week -48.95% -43.87% Year To Date -37.82% -24.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6320 CANOGA AVENUE 15TH FLOOR - WOODLAND HILLS,CA 91367 USA ph: 800-489-4774 fax: 818-230-9899 sbarnes@endonovo.com http://www.endonovo.com

• General Corporate Information    Officers Alan Collier - Chief Executive Officer; Interim Chief Financial O Michael Mann - Former President - - - - - - - - - Peer Information Endonovo Therapeutics, Inc. (CORR.) Endonovo Therapeutics, Inc. (RSPI) Endonovo Therapeutics, Inc. (CGXP) Endonovo Therapeutics, Inc. (BGEN) Endonovo Therapeutics, Inc. (GTBP) Endonovo Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29272H300 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/22/22 Share - Related Items Shares Outstanding: 139.58 Most Recent Split Date: 12.00 (0.00:1) Beta: 2.04 Market Capitalization: $1.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/22/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 33.58 EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -94.29% vs. Previous Quarter: 532.91% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -132.61 12/31/21 - -138.93 09/30/21 - -315.81 Current Ratio 03/31/22 - - 12/31/21 - 0.01 09/30/21 - 0.00 Quick Ratio 03/31/22 - - 12/31/21 - 0.01 09/30/21 - 0.00 Operating Margin 03/31/22 - -7,036.91 12/31/21 - -4,235.09 09/30/21 - -8,913.61 Net Margin 03/31/22 - -7,036.91 12/31/21 - -4,235.09 09/30/21 - -8,913.61 Pre-Tax Margin 03/31/22 - - 12/31/21 - -4,247.31 09/30/21 - -8,913.61 Book Value 03/31/22 - - 12/31/21 - -0.21 09/30/21 - -0.30 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©